A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase Expression in Stage II and III Colon Cancer

详细信息    查看全文

• 作者：Katarina Ö ; hrling¹ ; Mia Karlberg¹ ; ^{mia.karlberg@karolinska.se} ; David Edler² ; Marja Hallströ ; m¹ ; Peter Ragnhammar¹
• 关键词：Predictive markers ; Immunohistochemistry ; Adjuvant 5-FU
• 刊名：Clinical Colorectal Cancer
• 出版年：2013
• 出版时间：June, 2013
• 年：2013
• 卷：12
• 期：2
• 页码：128-135
• 全文大小：408 K

文摘

Background

Colon cancer with mismatch repair deficiency and low TS expression has been associated with an improved prognosis. Data also indicate that MMR proficient colon cancer with high TS expression has a better response to adjuvant 5-FU-based chemotherapy. This study evaluates if a combined analysis of MMR status and TS expression in colon cancer can add prognostic value and better predict response to adjuvant 5-FU-based chemotherapy. The potential relationship between MMR status and TS expression is also investigated.

Patients and Methods

This study includes a subgroup of 716 patients with colon cancer out of 2224 stage II and stage III colorectal cancer patients enrolled in Nordic trials randomized to surgery alone or surgery plus adjuvant 5-FU-based chemotherapy. After immunohistochemical analysis of tumor MMR status and TS expression the patients were divided into 4 groups.

Results

There was a nonsignificant difference in overall survival between group 1 (patients with deficient MMR tumors with low TS) and group 4 (patients with proficient MMR tumors expressing high TS). When comparing group 1 and group 4 patients treated with surgery alone a trend to better overall survival was found in group 1, P = .06. In group 4, stage III patients had a significantly improved survival when receiving adjuvant 5-FU-based chemotherapy compared with surgery alone, P = .01. No relationship was found between MMR status and TS expression.

Conclusions

A combined instead of a single marker analysis of MMR status and TS expression can improve the prediction of response to 5-FU-based chemotherapy in stage III colon cancer.